Opinion|Videos|August 19, 2024
Patient Access Advocacy for BTK Inhibitors
A panel of specialists discuss patient access advocacy for BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do changes in patient out-of-pocket costs under the IRA influence treatment and sequencing decisions?
- What strategies can healthcare providers use to advocate for patient access to BTK inhibitors?
Advertisement
Related to this article
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
4
CHEST Highlights Practice-Changing COPD Therapy and Strategies
5